2020 ICD-10-CM Diagnosis Code D05.1

Intraductal carcinoma in situ of breast

    2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
  • D05.1 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2020 edition of ICD-10-CM D05.1 became effective on October 1, 2019.
  • This is the American ICD-10-CM version of D05.1 - other international versions of ICD-10 D05.1 may differ.
The following code(s) above D05.1 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to D05.1:
  • C00-D49
    2020 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • D00-D09
    2020 ICD-10-CM Range D00-D09

    In situ neoplasms

    Includes
    • Bowen's disease
    • erythroplasia
    • grade III intraepithelial neoplasia
    • Queyrat's erythroplasia
    In situ neoplasms
  • D05
    ICD-10-CM Diagnosis Code D05

    Carcinoma in situ of breast

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • carcinoma in situ of skin of breast (D04.5)
    • melanoma in situ of breast (skin) (D03.5)
    • Paget's disease of breast or nipple (C50.-)
    Carcinoma in situ of breast
Clinical Information
  • (duk-tal kar-sin-o-ma in sye-too) dcis. Abnormal cells that involve only the lining of a duct. The cells have not spread outside the duct to other tissues in the breast. Also called intraductal carcinoma.
  • A carcinoma entirely confined to the mammary ducts. It is also known as dcis. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: high-grade dcis, intermediate-grade dcis and low-grade dcis. In this classification the dcis grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for dcis.
  • A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
  • A noninvasive condition in which abnormal cells are found in the lining of a breast duct. The abnormal cells have not spread outside the duct to other tissues in the breast. In some cases, ductal carcinoma in situ may become invasive cancer and spread to other tissues, although it is not known at this time how to predict which lesions will become invasive.
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change

Diagnosis Index entries containing back-references to D05.1:

ICD-10-CM Codes Adjacent To D05.1
D04.70 Carcinoma in situ of skin of unspecified lower limb, including hip
D04.71 Carcinoma in situ of skin of right lower limb, including hip
D04.72 Carcinoma in situ of skin of left lower limb, including hip
D04.8 Carcinoma in situ of skin of other sites
D04.9 Carcinoma in situ of skin, unspecified
D05 Carcinoma in situ of breast
D05.0 Lobular carcinoma in situ of breast
D05.00 Lobular carcinoma in situ of unspecified breast
D05.01 Lobular carcinoma in situ of right breast
D05.02 Lobular carcinoma in situ of left breast
D05.1 Intraductal carcinoma in situ of breast
D05.10 Intraductal carcinoma in situ of unspecified breast
D05.11 Intraductal carcinoma in situ of right breast
D05.12 Intraductal carcinoma in situ of left breast
D05.8 Other specified type of carcinoma in situ of breast
D05.80 Other specified type of carcinoma in situ of unspecified breast
D05.81 Other specified type of carcinoma in situ of right breast
D05.82 Other specified type of carcinoma in situ of left breast
D05.9 Unspecified type of carcinoma in situ of breast
D05.90 Unspecified type of carcinoma in situ of unspecified breast
D05.91 Unspecified type of carcinoma in situ of right breast

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.